CP-99,219 is a trifluoronaphthyridone with significant antibacterial activity that includes the family Enterobacteraceae (MICs for 90% of the strains tested [MIC90s], <0.015 to 0.5 ,ug/ml), MoraxeUla catarrhalis, Haemophilus influenzae, and gonococci (MICs, <0.015 p.g/ml). LegioneUla spp. were also CP-99,219 susceptible, with MICs of 0.008 to 0.12 ,ug/ml. 219 demonstrated activity greater than that of ciprofloxacin, ofloxacin, or enoxacin against Pseudomonas aeruginosa (MICg., 1 p,g/ml), Xanthomonas maltophilia (MIC90, 2 ,ug/ml), Staphylococcus haemolyticus (MIC90, 0.5 ,ug/ml), Enterococcus faecalis (MIC90, 1 ,ug/ml), and pneumococci (MIC90, 0.12 ,ug/ml). Numerous ciprofloxacin-resistant isolates were susceptible to 219, a new compound showing potential value for further in vivo trials.
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CP-99,219 is a novel investigational fluoroquinolone with a structure differing from those of norfloxacin, ciprofloxacin, and enoxacin (1, 2, 4, 8) . It contains the C-7 ring moiety 7-(3-azabicyclo[3.1.0]hexyl) on a basic naphthyridone configuration. The bicyclo C-7 substitution has been previously evaluated and described in CP-74,667 (5). The 1-N substitution of CP-99,219 is a difluorinated structure identical to that of tosufloxacin (3, 10) that produces enhanced activity against some ciprofloxacin-resistant organisms. In this study, we compared CP-99,219 activity with those of four clinically available quinolones (ciprofloxacin, enoxacin, norfloxacin, and ofloxacin) by using standardized methods.
Isolates Providencia stuartii (10) Salmonella enteritidis (10) Serratia marcescens (20) Shigella spp. (10) Yersinia enterocolitica (10) Acinetobacter spp. cology, and other in vitro characteristics appear to be indicated.
